Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 trialWJ Sandborn, J F Colombel, Walter Reinisch et al.|Zeitschrift für Gastroenterologie|2005Cited by 51
Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from ACT 1 and ACT 2Sandborn, J.F. Colombel, Brian G. Feagan et al.|Inflammatory Bowel Diseases|2008Cited by 5
Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohnʼs diseaseBE Sands, B. Feagan, Christopher Gasink et al.|Inflammatory Bowel Diseases|2011Cited by 5
P005 ANALYSIS OF PREDICTORS OF RESPONSE MAINTENANCE TO CERTOLIZUMAB PEGOL IN PATIENTS WITH ACTIVE CROHN'S DISEASE: DATA FROM PRECISE 2S. Hanauer, W. Sandborn, Stefan Schreiber et al.|Journal of Crohn s and Colitis Supplements|2008Cited by 2
Improvement in health related quality of life in infliximab-treated moderate-to-severe active ulcerative colitis patientsB E Sands, Walter Reinisch, B. Feagan et al.|Inflammatory Bowel Diseases|2007Cited by 1